RECURRENT ACUTE MYELOID LEUKEMIA

This study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…

This is an early safety study for a new oral medication called AOH1996 in adults with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The main goals are to find the safest dose and understand the drug's side effects. Researchers will also che…

This is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It is for older adults who are not candidates for standard intensive chemotherapy or for those whose disea…

This study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…

This study is testing a new approach to stem cell transplant for adults with aggressive blood cancers that have returned or not responded to treatment. The goal is to find the safest dose of radiation when combined with strong chemotherapy before the transplant, aiming to better …

This study is testing whether adding a newer drug called venetoclax to a standard, strong chemotherapy regimen works better for adults with acute myeloid leukemia (AML). The goal is to see if this combination is safe, find the best dose, and measure how well it controls the cance…

This early-stage study is testing a new drug called miRisten in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goals are to find a safe dose and check for side effects. Researchers hope the drug can slow or stop cancer…

This early-stage study is testing two new drug combinations for adults whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The first part combines tazemetostat with a standard chemotherapy drug (CPX-351). The second part tests a drug called palboc…

This early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…

This study is testing a new combination of three oral drugs (ASTX727, venetoclax, and gilteritinib) for adults with specific types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have a genetic change called an FLT3 mutation. The first part aims t…

This study tests whether combining two medicines—enasidenib and azacitidine—can help control acute myeloid leukemia that has returned or hasn't responded to previous treatments. It's for patients whose cancer has a specific genetic change called an IDH2 mutation. Researchers want…

This early-stage study is testing the safety and finding the best dose of a new two-drug combination (SNDX-5613 and gilteritinib) for adults with a specific form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The drugs work together to block two…

This study is testing a new combination of targeted drugs for people with advanced blood cancers that have a specific genetic change called an IDH1 mutation. The main goals are to find the safest dose and see how well the drug combo works to control the cancer. The trial is for a…

This study is testing a combination of two drugs, CPX-351 and quizartinib, to see if they can help control acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The main goals are to find the safest and most effective dose and to see how well the treatment wo…

This trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…

This study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…

This early-stage trial is testing a new combination of three drugs for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to other treatments. The goal is to find the safest and most effective dose by combining an immunot…

This study is testing a new treatment for aggressive blood cancers (like leukemia or MDS) that have come back or are not responding to standard therapies. The treatment involves a radioactive antibody designed to seek out and destroy cancer cells, followed by a stem cell transpla…

This is a first-in-human study to find a safe dose of a new drug called cirtuvivint for patients with advanced forms of blood cancer. The trial will test cirtuvivint by itself in patients whose cancer has returned or resisted treatment, and also test it combined with an existing …

This study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…

This study is testing whether combining two drugs, CPX-351 (a chemotherapy) and ivosidenib (a targeted pill), can help control a specific type of acute myeloid leukemia or high-risk MDS that has an IDH1 gene mutation. It will involve about 30 adults who are eligible for intensive…

This early-stage study is testing the safety and best dose of a new cell therapy called CD83 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to tar…

This study is testing a new combination of three drugs—azacitidine, venetoclax, and gilteritinib—for adults with certain aggressive blood cancers that have returned or not responded to treatment. The main goals are to find the safest dose and see if adding gilteritinib helps pati…

This early-stage trial is testing whether combining a new drug called 8-chloroadenosine with an existing cancer drug (venetoclax) is safe and tolerable for adults with acute myeloid leukemia that has come back or stopped responding to other treatments. The main goal is to find th…

This study is testing an oral drug called ONC201, alone or with another drug, for adults with advanced blood cancers that have returned or are not responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the treatment can help…

This study is testing a combination of two chemotherapy drugs, CPX-351 and venetoclax, for adults with acute myeloid leukemia (AML) that has come back after treatment or did not respond to initial therapy. The main goal is to see if this combination can put the cancer into remiss…

This study is testing a combination of three oral medications for adults with acute myeloid leukemia (AML) that has come back or not responded to prior treatment. The goal is to see if this new combination is safe and can help control the cancer. The trial will enroll about 84 pa…

This early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…

This study is testing a new type of personalized cell therapy called LILRA6 CAR-T for adults whose acute myeloid leukemia has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see if the therapy can help control the cancer. This is a…